CEO's presentation to AGM

ersonal use only

CEO Presentation to AGM

Professor Bernard Tuch

11 November 2021

www.lctglobal.com

ASX:LCT | OTCQB: LVCLY | www.lctglobal.com |

LCTglobal

Safe Harbour Statement

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of onlyforward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected",

"estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.

useIn particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other

There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities'

r quirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and dditional factors that involve significant risks and uncertainties about our products, product candidates, financial results and

business prospects.

Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

LCT is providing this information as of the date of this presentation and, subject to law, does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

ersonal	ASX:LCT | OTCQB: LVCLY | www.lctglobal.com |	LCTglobal

Agenda

ersonal use only

• Cash Position 2021
• Update NTCELL® for Parkinson's
• DIABECELL®
• LC-002for Migraine
• LP-003for Obesity

ASX:LCT | OTCQB: LVCLY | www.lctglobal.com |	LCTglobal	3

LCT Cash Position

only
 Dec 2021 ~ $5M, compared to ~$2M in Dec 2020
 NTCELL®
use	• Funding of $3.5M obtained with assistance of 180 Markets to
	initiate a 3-year study of early to mid stage Parkinson's disease
		to delay or halt natural disease progression
	• Rights issue to be launched on Monday seeks to raise $3.8M
 Callaghan Growth Grant ended in March 2021. Received $247K
ersonal	•	Replaced by R & D Incentive and Callaghan top up which

expires March 2022; 20% rebate to be applied for Dec 2021

 R & D Tax credit received $454K

ASX:LCT | OTCQB: LVCLY | www.lctglobal.com |	LCTglobal	4

ersonal use only

NTCELL® for Parkinson's disease

ASX:LCT | OTCQX: LVCLY | www.lctglobal.com |

LCTglobal